GLP1R and neurodegenerative disease: Future research focusing on the development of nonpeptidergic ligands that could possibly modify the activity of the GLP-1R itself, maximizing the potent effects of GLP-1R agonists at multiple levels, could possibly offer greater benefits in the treatment of PD, as well as of other neurodegenerative diseases.